Juxtarenal Aortic AneurysmNCT04773223
Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment
An observational study of Juxtarenal Aortic Aneurysm and Pararenal Aneurysm, run by Clinical Centre of Serbia at 1 site in Serbia.
Trial summary
Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Juxtarenal Aortic Aneurysm, Pararenal Aneurysm
- What is being tested?
- Open surgery and complex EVAR due to AAA
- Type of treatment
- Surgery or procedure
- How many people
- 925 participants
- Where
- 1 siteSerbia
- Study dates
- 1 Jan 2011to 1 Jan 2022
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients with juxta/pararenal abdominal aortic aneurysm (AAA) undergoing either open surgery or complex endovascular repair. The definition of the juxtarenal AAA will include those with a short neck (less than 1cm). The definition of the pararenal AAA will include those where renal arteries originate from the aneurysm itself.
Who may be able to join
- All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2022
- All management strategies will be included (endovascular and open)
Who cannot join
- Patients who are pregnant
- Patients who are under 18 years of age
- Patients who have ruptured AAA
- Patients with thoracoabdominal aortic aneurysm (ThAAA)
- Patients who have a mycotic AAA
- Patients with connective tissue disorder
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Endovascular and Open Repair of Juxta- and Pararenal Abdominal Aortic Aneurysm on Short- and Long-term Clinical Outcomes
Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR).
Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA.
Read more
Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities.
Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.
Read the detailed description
Background Endovascular abdominal aortic aneurysm repair (EVAR) has gained widespread acceptance in the treatment of patients with abdominal aortic aneurysms (AAA). Prospective randomized trials (RCTs) have demonstrated several short-term advantages over open repair such as less blood loss, operative time, hospital stay, morbidity, and mortality. The applicability of EVAR is limited by the presence of inadequate neck or involvement of the visceral arteries. Thus consequently open AAA repair is now being performed primarily for complex aortic anatomies, such as juxtarenal and pararenal aneurysms. Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate and low morbidity and mortality with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Vascular surgeons are therefore left with a paucity of data to guide decision-making.
Study objectives:
- Primary aim: Compare Kaplan-Meier freedom from aortic related reintervention and all-cause mortality rate between endovascular and open repair group Primary endpoint: Kaplan-Meier survival rate and Kaplan-Meier aortic related reintervention rate after the patient recruitment ends
- Secondary aim: compare short term outcomes in terms of 30-day complications rate, especially acute kidney injury according to the RIFLE criteria Secondary endpoint: 30-day complications rate, especially acute kidney injury according to the RIFLE criteria
Inclusion criteria:
- All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2021
- All management strategies will be included (endovascular and open)
Exclusion criteria:
- Patients who are pregnant
- Patients who are under 18 years of age
- Patients who have ruptured AAA
- Patients with thoracoabdominal aortic aneurysm (ThAAA)
- Patients who have a mycotic AAA
- Patients with connective tissue disorder
Sample size To ensure sufficient statistical power to answer hypothetical questions, approximately 700 subjects will be entered into the database. Aortic-related reintervention rate is the primary endpoint being used to calculate the sample size. Assuming a difference of 7% in the late reintervention rate between endovascular and open repair, 221 patients would be required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (endovascular versus open), assuming a 20% rate of missing data, a total N of 550 patients is required.
Research Design
This is a prospective study including patients treated for juxta- and pararenal AAA from 2011 through 2021 treated at six different vascular surgery centers:
- Clinic for Vascular and Endovascular Surgery, Belgrade, Serbia
- Department of Vascular Surgery, Policlinico S. Orsola-Malpighi, Bologna, Italy
- Department of Vascular Surgery, San Raffaele Hospital, Milan, Italy
- Department of Vascular Surgery, Dijklander Ziekenhuis, Hoorn, Netherlands
- Department of Vascular Surgery, Amsterdam University Hospital, Amsterdam, Netherlands
- Department of Vascular Surgery, Helsinki Unversity Hospital, Helsinki, Finland
Procedures Involved The study does not involve any patient contact and will not impact the care that patients receive. Data regarding the patients will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, and comorbidities, diagnostic imaging information, laboratory data, surgical procedure information, complications of the surgery, and outcomes.
Multi-Institutional research After the data has been collected at a participating institution, the data will be transmitted to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/Clinical Center of Serbia/Medical Faculty, University of Belgrade.
Risks to Subjects As this is a prospective observational study, there is no potential for physical risks to subjects. There is a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information.
Potential Benefits to Subjects There is no direct benefit to the subjects. However, future patients with juxta- and pararenal AAA may benefit from improved care as a result of this study.
Statistics and Data Analysis Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and were compared using the chi-square test or Fisher exact test. Propensity score analysis will be performed by matching endovascular to open surgery group in a 1:1 ratio controlling for demographics, baseline comorbidities, and AAA parameters. Differences will be considered statistically significant at p < 0.05. The cumulative incidences of all-cause mortality and aortic-related complications will be estimated using the Kaplan-Meier method. Differences between curves will be tested using the log-rank test. Analyses will be done with SPSS software, version 20.0 (SPSS, Chicago, IL, USA).
Conflict of Interest The investigators have no conflict of interest to report.
Funding Source There are no plans to apply for grants or additional funding. No funding is required for the completion of this study.
Publication Plan All research personnel listed on this protocol will be eligible for authorship in any resulting abstracts and publications in accordance with the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.
- Conditions
- Juxtarenal Aortic Aneurysm, Pararenal Aneurysm
- Being tested
- Open surgery and complex EVAR due to AAA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Open surgery and complex EVAR due to AAAProcedure or surgery
There will be two cohorts:
- Patient undergoing open surgery
- Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)
| Study group | Role | What they receive |
|---|---|---|
| Open surgery group | Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm Receives: Procedure: Open surgery and complex EVAR due to AAA | |
| Endovascular group | Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc. Receives: Procedure: Open surgery and complex EVAR due to AAA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Aortic Related Reintervention.
In open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.
Measured: through study completion, an average of 7 year
All-cause Mortality
Any cause of mortality duing follow-up period
Measured: through study completion, an average of 7 year
Secondary outcomes (1)
30-day Acute Kidney Injury
Acute kidney injury was defined using RIFFLE criteria.
Measured: 30-day acute kidney injury
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2021
- Study start1 Jan 2011
- Primary completion1 Jan 2022
- Study completion1 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Juxtarenal Aortic AneurysmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 925 participants (actual)
Sponsor and investigators
- Lead sponsor
- Clinical Centre of Serbia
- Sponsor type
- University, hospital or other
- Collaborators
- Università Vita-Salute San Raffaele, Helsinki University Central Hospital, Dijklander Ziekenhuis, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Responsible party
- Principal investigator, Petar Zlatanovic, Clinical Centre of Serbia
- Investigators
- Petar Zlatanovic, MD, Principal investigator, University Clinical Centre of Serbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04773223
- Sponsor's protocol ID
- Complex AAA surgery
- Status last verified
- Feb 2024
- First submitted
- 20 Feb 2021
- Last updated
- 22 Jul 2024
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This will be not available freely online, but on the request.
Publications
Tinelli G, Crea MA, de Waure C, Di Tanna GL, Becquemin JP, Sobocinski J, Snider F, Haulon S. A propensity-matched comparison of fenestrated endovascular aneurysm repair and open surgical repair of pararenal and paravisceral aortic aneurysms. J Vasc Surg. 2018 Sep;68(3):659-668. doi: 10.1016/j.jvs.2017.12.060. Epub 2018 Mar 22.
PubMed 29576405Raux M, Patel VI, Cochennec F, Mukhopadhyay S, Desgranges P, Cambria RP, Becquemin JP, LaMuraglia GM. A propensity-matched comparison of outcomes for fenestrated endovascular aneurysm repair and open surgical repair of complex abdominal aortic aneurysms. J Vasc Surg. 2014 Oct;60(4):858-63; discussion 863-4. doi: 10.1016/j.jvs.2014.04.011. Epub 2014 May 15.
PubMed 24835042Roy IN, Millen AM, Jones SM, Vallabhaneni SR, Scurr JRH, McWilliams RG, Brennan JA, Fisher RK. Long-term follow-up of fenestrated endovascular repair for juxtarenal aortic aneurysm. Br J Surg. 2017 Jul;104(8):1020-1027. doi: 10.1002/bjs.10524. Epub 2017 Apr 12.
PubMed 28401533Ferrante AM, Moscato U, Colacchio EC, Snider F. Results after elective open repair of pararenal abdominal aortic aneurysms. J Vasc Surg. 2016 Jun;63(6):1443-50. doi: 10.1016/j.jvs.2015.12.034. Epub 2016 Mar 16.
PubMed 26994948Zlatanovic P, Davidovic L, Mascia D, Ancetti S, Yeung KK, Jongkind V, Viitala H, Venermo M, Wiersema A, Chiesa R, Gargiulo M. Acute kidney injury in patients undergoing endovascular or open repair of juxtarenal or pararenal aortic aneurysms. J Vasc Surg. 2024 Jun;79(6):1347-1359.e3. doi: 10.1016/j.jvs.2024.02.021. Epub 2024 Feb 22.
PubMed 38395093
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Endovascular and Open Repair of Juxta- and Pararenal Abdominal Aortic Aneurysm on Short- and Long-term Clinical Outcomes
- ClinicalTrials.gov ID
- NCT04773223
- Acronym / sponsor ID
- Complex AAA surgery
- Conditions
- Juxtarenal Aortic Aneurysm, Pararenal Aneurysm
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 925 participants (actual)
- Lead sponsor
- Clinical Centre of SerbiaUniversity, hospital or other
- Collaborators
- Università Vita-Salute San Raffaele, Helsinki University Central Hospital, Dijklander Ziekenhuis, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study start
- 1 Jan 2011 (actual)
- Primary completion
- 1 Jan 2022 (actual)
- Study completion
- 1 Jan 2022 (actual)
- First posted
- 26 Feb 2021 (actual)
- Results
- Posted 22 Jul 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR).
Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA.
Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities.
Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.
Detailed description
Background Endovascular abdominal aortic aneurysm repair (EVAR) has gained widespread acceptance in the treatment of patients with abdominal aortic aneurysms (AAA). Prospective randomized trials (RCTs) have demonstrated several short-term advantages over open repair such as less blood loss, operative time, hospital stay, morbidity, and mortality. The applicability of EVAR is limited by the presence of inadequate neck or involvement of the visceral arteries. Thus consequently open AAA repair is now being performed primarily for complex aortic anatomies, such as juxtarenal and pararenal aneurysms. Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate and low morbidity and mortality with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Vascular surgeons are therefore left with a paucity of data to guide decision-making.
Study objectives:
- Primary aim: Compare Kaplan-Meier freedom from aortic related reintervention and all-cause mortality rate between endovascular and open repair group Primary endpoint: Kaplan-Meier survival rate and Kaplan-Meier aortic related reintervention rate after the patient recruitment ends
- Secondary aim: compare short term outcomes in terms of 30-day complications rate, especially acute kidney injury according to the RIFLE criteria Secondary endpoint: 30-day complications rate, especially acute kidney injury according to the RIFLE criteria
Inclusion criteria:
- All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2021
- All management strategies will be included (endovascular and open)
Exclusion criteria:
- Patients who are pregnant
- Patients who are under 18 years of age
- Patients who have ruptured AAA
- Patients with thoracoabdominal aortic aneurysm (ThAAA)
- Patients who have a mycotic AAA
- Patients with connective tissue disorder
Sample size To ensure sufficient statistical power to answer hypothetical questions, approximately 700 subjects will be entered into the database. Aortic-related reintervention rate is the primary endpoint being used to calculate the sample size. Assuming a difference of 7% in the late reintervention rate between endovascular and open repair, 221 patients would be required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (endovascular versus open), assuming a 20% rate of missing data, a total N of 550 patients is required.
Research Design
This is a prospective study including patients treated for juxta- and pararenal AAA from 2011 through 2021 treated at six different vascular surgery centers:
- Clinic for Vascular and Endovascular Surgery, Belgrade, Serbia
- Department of Vascular Surgery, Policlinico S. Orsola-Malpighi, Bologna, Italy
- Department of Vascular Surgery, San Raffaele Hospital, Milan, Italy
- Department of Vascular Surgery, Dijklander Ziekenhuis, Hoorn, Netherlands
- Department of Vascular Surgery, Amsterdam University Hospital, Amsterdam, Netherlands
- Department of Vascular Surgery, Helsinki Unversity Hospital, Helsinki, Finland
Procedures Involved The study does not involve any patient contact and will not impact the care that patients receive. Data regarding the patients will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, and comorbidities, diagnostic imaging information, laboratory data, surgical procedure information, complications of the surgery, and outcomes.
Multi-Institutional research After the data has been collected at a participating institution, the data will be transmitted to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/Clinical Center of Serbia/Medical Faculty, University of Belgrade.
Risks to Subjects As this is a prospective observational study, there is no potential for physical risks to subjects. There is a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information.
Potential Benefits to Subjects There is no direct benefit to the subjects. However, future patients with juxta- and pararenal AAA may benefit from improved care as a result of this study.
Statistics and Data Analysis Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and were compared using the chi-square test or Fisher exact test. Propensity score analysis will be performed by matching endovascular to open surgery group in a 1:1 ratio controlling for demographics, baseline comorbidities, and AAA parameters. Differences will be considered statistically significant at p < 0.05. The cumulative incidences of all-cause mortality and aortic-related complications will be estimated using the Kaplan-Meier method. Differences between curves will be tested using the log-rank test. Analyses will be done with SPSS software, version 20.0 (SPSS, Chicago, IL, USA).
Conflict of Interest The investigators have no conflict of interest to report.
Funding Source There are no plans to apply for grants or additional funding. No funding is required for the completion of this study.
Publication Plan All research personnel listed on this protocol will be eligible for authorship in any resulting abstracts and publications in accordance with the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Open surgery group | – | Procedure: Open surgery and complex EVAR due to AAAPatients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm |
| Endovascular group | – | Procedure: Open surgery and complex EVAR due to AAAPatients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients with juxta/pararenal abdominal aortic aneurysm (AAA) undergoing either open surgery or complex endovascular repair. The definition of the juxtarenal AAA will include those with a short neck (less than 1cm). The definition of the pararenal AAA will include those where renal arteries originate from the aneurysm itself.
Key inclusion criteria (2 listed)
- All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2022
- All management strategies will be included (endovascular and open)
Key exclusion criteria (6 listed)
- Patients who are pregnant
- Patients who are under 18 years of age
- Patients who have ruptured AAA
- Patients with thoracoabdominal aortic aneurysm (ThAAA)
- Patients who have a mycotic AAA
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Open surgery and complex EVAR due to AAAThere will be two cohorts: 1. Patient undergoing open surgery 2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.) | Procedure or surgery | Endovascular group, Open surgery group |
Primary outcome
Aortic Related Reintervention.
Time frame: through study completion, an average of 7 year
In open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.
All-cause Mortality
Time frame: through study completion, an average of 7 year
Any cause of mortality duing follow-up period
1 secondary outcome
30-day Acute Kidney Injury
Time frame: 30-day acute kidney injury
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 29576405Tinelli G, Crea MA, de Waure C, Di Tanna GL, Becquemin JP, Sobocinski J, Snider F, Haulon S. A propensity-matched comparison of fenestrated endovascular aneurysm repair and open surgical repair of pararenal and paravisceral aortic aneurysms. J Vasc Surg. 2018 Sep;68(3):659-668. doi: 10.1016/j.jvs.2017.12.060. Epub 2018 Mar 22.
- Background: PubMed 24835042Raux M, Patel VI, Cochennec F, Mukhopadhyay S, Desgranges P, Cambria RP, Becquemin JP, LaMuraglia GM. A propensity-matched comparison of outcomes for fenestrated endovascular aneurysm repair and open surgical repair of complex abdominal aortic aneurysms. J Vasc Surg. 2014 Oct;60(4):858-63; discussion 863-4. doi: 10.1016/j.jvs.2014.04.011. Epub 2014 May 15.
- Background: PubMed 28401533Roy IN, Millen AM, Jones SM, Vallabhaneni SR, Scurr JRH, McWilliams RG, Brennan JA, Fisher RK. Long-term follow-up of fenestrated endovascular repair for juxtarenal aortic aneurysm. Br J Surg. 2017 Jul;104(8):1020-1027. doi: 10.1002/bjs.10524. Epub 2017 Apr 12.
- Background: PubMed 26994948Ferrante AM, Moscato U, Colacchio EC, Snider F. Results after elective open repair of pararenal abdominal aortic aneurysms. J Vasc Surg. 2016 Jun;63(6):1443-50. doi: 10.1016/j.jvs.2015.12.034. Epub 2016 Mar 16.
- Derived from this study: PubMed 38395093Zlatanovic P, Davidovic L, Mascia D, Ancetti S, Yeung KK, Jongkind V, Viitala H, Venermo M, Wiersema A, Chiesa R, Gargiulo M. Acute kidney injury in patients undergoing endovascular or open repair of juxtarenal or pararenal aortic aneurysms. J Vasc Surg. 2024 Jun;79(6):1347-1359.e3. doi: 10.1016/j.jvs.2024.02.021. Epub 2024 Feb 22.
- Individual participant dataSharing planned: No. This will be not available freely online, but on the request.
Related trials for Juxtarenal Aortic Aneurysm
Recruiting
Zenith® Fenestrated+ Clinical Study
Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm
Recruiting
Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms
Technical Sucess, Freedom From Type I and III Endoleaks at 12 Months
Not yet recruiting
Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm
Aneurysm Aortic
Active, not recruitingObservational study
Endurant CHevAr New Indication Trial: ENCHANT
AAA - Abdominal Aortic Aneurysm
Recruiting
University of Utah PS-IDE: Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms
Juxtarenal Abdominal Aortic Aneurysm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Petar Zlatanovic, MD principal investigator
University Clinical Centre of Serbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Juxtarenal Aortic Aneurysm and Pararenal Aneurysm, run by Clinical Centre of Serbia at 1 site in Serbia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Serbia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jul 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Aortic Related Reintervention. (time frame: through study completion, an average of 7 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04773223, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2024.